- Home
- JANX vs NAD Comparison
JANX vs NAD Comparison
Compare JANX & NAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JANX
- NAD
- Stock Information
- Founded
- JANX 2017
- NAD 1999
- Country
- JANX United States
- NAD United States
- Employees
- JANX 103
- NAD N/A
- Industry
- JANX Biotechnology: Pharmaceutical Preparations
- NAD Investment Managers
- Sector
- JANX Health Care
- NAD Finance
- Exchange
- JANX Nasdaq
- NAD Nasdaq
- Market Cap
- JANX 1.4B
- NAD 2.6B
- IPO Year
- JANX 2021
- NAD N/A
- Fundamental
- Price
- JANX $24.40
- NAD $11.66
- Analyst Decision
- JANX Strong Buy
- NAD
- Analyst Count
- JANX 11
- NAD 0
- Target Price
- JANX $76.55
- NAD N/A
- AVG Volume (30 Days)
- JANX 610.9K
- NAD 595.7K
- Earning Date
- JANX 11-05-2025
- NAD 01-01-0001
- Dividend Yield
- JANX N/A
- NAD 4.35%
- EPS Growth
- JANX N/A
- NAD N/A
- EPS
- JANX N/A
- NAD N/A
- Revenue
- JANX $439,000.00
- NAD N/A
- Revenue This Year
- JANX N/A
- NAD N/A
- Revenue Next Year
- JANX $130.50
- NAD N/A
- P/E Ratio
- JANX N/A
- NAD N/A
- Revenue Growth
- JANX N/A
- NAD N/A
- 52 Week Low
- JANX $21.97
- NAD $9.56
- 52 Week High
- JANX $71.71
- NAD $11.64
- Technical
- Relative Strength Index (RSI)
- JANX 52.58
- NAD 61.17
- Support Level
- JANX $23.15
- NAD $11.27
- Resistance Level
- JANX $24.79
- NAD $11.82
- Average True Range (ATR)
- JANX 1.16
- NAD 0.09
- MACD
- JANX 0.05
- NAD 0.02
- Stochastic Oscillator
- JANX 62.58
- NAD 61.72
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About NAD Nuveen Quality Municipal Income Fund
Nuveen Quality Municipal Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide current income exempted from regular federal income tax by investing in tax-exempt municipal securities that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.